Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

← catalyst calendar

NCT05375994

Sponsored by Verastem, Inc. (industry) · VSTM — their whole pipeline →. With Mirati Therapeutics Inc..

Phase

Phase 1/2

Status

Completed

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

12actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-08-01

actual

When the study began enrolling

Primary completion

2026-06-15

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-06-15

actual

The whole study's end, after follow-up

First posted

2022-05-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non Small Cell Lung Cancer
KRAS Activating Mutation
Advanced Cancer
Metastatic Cancer
Malignant Neoplasm of Lung
Malignant Neoplastic Disease

Intervention

Drug: avutometinib (VS-6766) and adagrasib — also filed as KRAS G12C Inhibitor, adagrasib, KRAZATI®

Primary outcomes

what the primary-completion date above is the date OF

Part A: To determine RP2D for avutometinib(VS-6766) in combination with adagrasib

measured From start of treatment to confirmation of RP2D; 28 days

To determine the efficacy of the optimal regimen identified from Part A

measured From start of treatment to confirmation of response; 16 weeks

Permalink · VSTM's whole pipeline · Catalyst calendar · Every registered study · What changed